MX2007010962A - Uso de una combinacion de virus myxoma y rapamicina para tratamiento terapeutico. - Google Patents

Uso de una combinacion de virus myxoma y rapamicina para tratamiento terapeutico.

Info

Publication number
MX2007010962A
MX2007010962A MX2007010962A MX2007010962A MX2007010962A MX 2007010962 A MX2007010962 A MX 2007010962A MX 2007010962 A MX2007010962 A MX 2007010962A MX 2007010962 A MX2007010962 A MX 2007010962A MX 2007010962 A MX2007010962 A MX 2007010962A
Authority
MX
Mexico
Prior art keywords
rapamycin
combination
myxoma virus
therapeutic treatment
cells
Prior art date
Application number
MX2007010962A
Other languages
English (en)
Inventor
Grant Mcfadden
John Barrett
Marianne Stanford
Original Assignee
Robarts Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Robarts Res Inst filed Critical Robarts Res Inst
Publication of MX2007010962A publication Critical patent/MX2007010962A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La presente invencion se refiere al uso terapeutico de una combinacion del virus Myxoma, inclusive en combinacion con rapamicina. El tratamiento con rapamicina aumenta la capacidad del virus Myxoma para infectar selectivamente las celulas que tienen una respuesta antiviral innata deficiente, inclusive las celulas que no son sensibles al interferon. La combinacion de rapamicina y el virus Myxoma puede utilizarse para tratar enfermedades caracterizadas por la presencia de estas celulas, inclusive cancer. La invencion tambien se refiere al uso terapeutico del virus Myxoma que no expresa la proteina funcional M135R. La figura mas representativa de la invencion es la numero 31.
MX2007010962A 2005-03-07 2006-03-06 Uso de una combinacion de virus myxoma y rapamicina para tratamiento terapeutico. MX2007010962A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65881605P 2005-03-07 2005-03-07
PCT/CA2006/000315 WO2006094385A1 (en) 2005-03-07 2006-03-06 Use of a combination of myxoma virus and rapamycin for therapeutic treatment

Publications (1)

Publication Number Publication Date
MX2007010962A true MX2007010962A (es) 2008-03-10

Family

ID=36952904

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007010962A MX2007010962A (es) 2005-03-07 2006-03-06 Uso de una combinacion de virus myxoma y rapamicina para tratamiento terapeutico.

Country Status (15)

Country Link
US (5) US20090035276A1 (es)
EP (2) EP1863906A4 (es)
JP (2) JP2008531739A (es)
KR (1) KR101479093B1 (es)
CN (2) CN102357104B (es)
AU (1) AU2006222500B2 (es)
CA (1) CA2600675C (es)
DK (1) DK2388315T3 (es)
HK (1) HK1163175A1 (es)
IL (2) IL185376A0 (es)
MX (1) MX2007010962A (es)
NZ (2) NZ560840A (es)
RU (1) RU2461630C2 (es)
UA (1) UA96412C2 (es)
WO (1) WO2006094385A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2600675C (en) 2005-03-07 2015-12-15 Robarts Research Institute Use of a combination of myxoma virus and rapamycin for therapeutic treatment
US8512713B2 (en) * 2006-06-01 2013-08-20 Robarts Research Institute Myxoma virus mutants for cancer treatment
CN102124335B (zh) * 2008-05-22 2014-07-30 第一药品株式会社 基于肿瘤抑制因子的过度增生细胞对溶瘤病毒疗法的敏感性
US20120100109A1 (en) * 2010-10-26 2012-04-26 Xiaoliu Zhang Method for increasing the replication of oncolytic HSVs in highly resistant tumor cells using mTOR pathway and PI3K inhibitors
PT2717887T (pt) 2011-06-09 2018-04-04 Univ Florida Métodos para tratamento ou prevenção da doença do enxerto contra hospedeiro
RU2695136C1 (ru) * 2018-06-19 2019-07-22 Общество с ограниченной ответственностью Биотехнология (ООО Биотехнология) Онколитический способ терапии рака молочной железы.
CA3108897A1 (en) * 2018-08-08 2020-02-13 Arizona Board Of Regents On Behalf Of Arizona State University Method for improved poxvirus yields
US20210252086A1 (en) * 2018-09-05 2021-08-19 Arizona Board Of Regents On Behalf Of Arizona State University Oncolytic virus platform to treat hematological cancer
AU2020340934A1 (en) * 2019-09-02 2022-03-31 Arizona Board Of Regents On Behalf Of Arizona State University Methods and compositions for improving oncolytic virus infection for nonpermissive cancers
MX2022004323A (es) * 2019-10-10 2022-08-02 Univ Arizona State Virus oncoliticos que expresan captadores multiespecificos de celulas inmunitarias.
US20240091284A1 (en) * 2019-10-10 2024-03-21 Arizona Board Of Regents On Behalf Of Arizona State University Oncolytic virus comprising immunomodulatory transgenes and uses thereof
WO2022139440A1 (ko) * 2020-12-22 2022-06-30 바이로큐어 주식회사 신규한 재조합 믹소마바이러스 및 이의 용도

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4401653A (en) * 1981-03-09 1983-08-30 Ayerst, Mckenna & Harrison Inc. Combination of rapamycin and picibanil for the treatment of tumors
US4806347A (en) 1985-12-11 1989-02-21 Schering Corporation Interferon combinations
GB9415320D0 (en) 1994-07-29 1994-09-21 Medical Res Council Cancer treatment
AU1550797A (en) 1996-01-25 1997-08-20 Medical Research Council Treatment of non-neuronal cancer using hsv mutant
WO1999004026A2 (en) 1997-07-18 1999-01-28 Chiron Corporation Lentiviral vectors
US7041654B2 (en) * 1997-10-03 2006-05-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods and compositions for inducing tumor-specific cytotoxicity
DE69838340T2 (de) 1997-10-09 2008-05-21 Wellstat Biologics Corp. Behandlung von neoplasmen mit interferonempfindlichen, klonalen viren
US6264940B1 (en) * 1998-08-05 2001-07-24 The Research Foundation Of State University Of New York Recombinant poliovirus for the treatment of cancer
WO2001004318A2 (en) 1999-07-12 2001-01-18 Viron Therapeutics, Inc. Myxoma virus genes for immune modulation
CA2388807C (en) 1999-11-12 2013-08-06 Matthew C. Coffey Viruses for the treatment of cellular proliferative disorders
AU2001261738A1 (en) * 2000-05-17 2001-11-26 London Health Sciences Centre Compositions and methods for promoting immunosuppression
PT2269603E (pt) * 2001-02-19 2015-09-09 Novartis Ag Tratamento de tumores da mama com um derivado de rapamicina em combinação com exemestano
UA77200C2 (en) 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
EP2044948B1 (en) * 2002-08-12 2013-10-30 Jennerex Biotherapeutics ULC Vaccinia viruses for use in treating cancer
AU2004216928B2 (en) * 2003-03-07 2007-03-08 Robarts Research Institute Use of myxoma virus for the therapeutic treatment of cancer and chronic viral infection
US20040258662A1 (en) * 2003-04-22 2004-12-23 Wyeth Antineoplastic agents
WO2005002607A2 (en) * 2003-07-07 2005-01-13 Oncolytics Biotech Inc. Oncolytic reoviruses for the treatment of neoplasms having activated pp2a or rac
JP5170741B2 (ja) * 2004-04-27 2013-03-27 ウェルスタット バイオロジクス コーポレイション ウイルスおよびカンプトテシン類を使用する癌の処置
CA2600675C (en) 2005-03-07 2015-12-15 Robarts Research Institute Use of a combination of myxoma virus and rapamycin for therapeutic treatment

Also Published As

Publication number Publication date
NZ577283A (en) 2010-11-26
WO2006094385A1 (en) 2006-09-14
US20140134134A1 (en) 2014-05-15
JP5674210B2 (ja) 2015-02-25
EP2388315B1 (en) 2014-05-21
NZ560840A (en) 2009-07-31
CN102357104A (zh) 2012-02-22
EP2388315A2 (en) 2011-11-23
EP1863906A1 (en) 2007-12-12
IL185376A0 (en) 2008-02-09
US20110195050A1 (en) 2011-08-11
CN101137748A (zh) 2008-03-05
KR20070110423A (ko) 2007-11-16
IL208070A (en) 2015-06-30
CA2600675C (en) 2015-12-15
CA2600675A1 (en) 2006-09-14
DK2388315T3 (da) 2014-08-25
IL208070A0 (en) 2010-12-30
CN102357104B (zh) 2016-01-27
CN101137748B (zh) 2011-12-14
UA96412C2 (ru) 2011-11-10
US20130171106A1 (en) 2013-07-04
RU2007137008A (ru) 2009-04-20
EP1863906A4 (en) 2009-06-03
AU2006222500B2 (en) 2011-09-01
HK1163175A1 (en) 2012-09-07
AU2006222500A1 (en) 2006-09-14
EP2388315A3 (en) 2012-05-02
JP2012236860A (ja) 2012-12-06
US20090035276A1 (en) 2009-02-05
US20180256656A1 (en) 2018-09-13
JP2008531739A (ja) 2008-08-14
US9987315B2 (en) 2018-06-05
RU2461630C2 (ru) 2012-09-20
KR101479093B1 (ko) 2015-01-26

Similar Documents

Publication Publication Date Title
UA96412C2 (ru) Применение комбинации вируса миксомы и рапамицина для лечения
GB2506085A (en) Combination treatment (eg with ABT-072 or ABT-333) of DAAS for use in treating HCV
WO2008045238A3 (en) Stabilized therapeutic small helical antiviral peptides
HK1139656A1 (en) Tetrahydrofuro [3,4-d] dioxolane compounds for use in the treatment of viral infections and cancer
TW200732347A (en) VEGF analogs and methods of use
WO2009149179A3 (en) Enhanced antiviral therapy methods and devices
TW200833662A (en) 4,5-ring annulated indole derivatives and methods of use thereof
WO2008127710A3 (en) Methods for treating cancer resistant to erbb therapeutics
GB2506086A (en) Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon
TW200744618A (en) Use of local immune suppression to enhance oncolytic viral therapy
WO2007076161A3 (en) Compounds with therapeutic activity
ATE363896T1 (de) Gegen missbrauch gesicherte darreichungsform
MX2011007195A (es) Derivado de ciclosporina para el uso en el tratamiento de infección de virus de hepatitis c (vhc) y virus de inmunodeficiencia humana (vih).
TW200510343A (en) Substituted dihydroquinazolines
TW200733974A (en) Materials and methods for treating chronic fibrotic disease
MX2021008036A (es) Bioplaguicidas para la enfermedad tizon tardio de la papa.
CL2014002557A1 (es) Compuestos bicíclicos de pirazinona; procedimiento de preparacion; composicion farmaceutica; kit; y uso en el tratamiento y/o prevencion de enfermedades cardiovasculares, cancer, entre otras.
MX2009012598A (es) Formas de dosis que comprenden vx-950 y su regimen de dosificacion.
SG155898A1 (en) Treatment of diseases using nalmefene and its analogs
MXPA05009526A (es) Uso de virus de mixoma para el tratamiento terapeutico de cancer e infeccion viral cronica.
MX2010004892A (es) Terapia de combinacion para tratar infecciones virales persistentes.
WO2007150008A3 (en) Polypeptides from african swine virus as vaccines for preventive and therapeutic use
CA3076277A1 (en) Method for treating cancer with a coxsackievirus b3 (cvb3) variant
WO2007027321A3 (en) Therapeutic antibodies for treatment and prophylaxis of transmittable viral diseases
UA91501C2 (ru) Индукторы монопараиммунитета, основанные на ослабленных вирусах миксомы кролика

Legal Events

Date Code Title Description
FG Grant or registration